Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA study of garetosmab versus placebo in adults with fibrodysplasia ossificans progressiva
NL-OMON60304Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing Garetosmab IV with Placebo IV (2 arms). Primary endpoints: Number of new heterotopic ossification lesions and Incidence and severity of treatment-emergent adverse events of special interest. Started Jan 2024; status: completed.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NL-OMON60304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60304.